Synthesis and structure activity relationship of the first class of LXR inverse agonists
Document Type
Article
Publication Title
Bioorganic Chemistry
Abstract
Liver X Receptors (LXRs) are members of the nuclear receptor family, and they play significant role in lipid and cholesterol metabolism. Moreover, they are key regulators of several inflammatory pathways. Pharmacological modulation of LXRs holds great potential in treatment of metabolic diseases, neurodegenerative diseases, and cancer. We were the first group to identify LXR inverse agonists SR9238 (6) and SR9243 (7) and demonstrate their potential utility in treating liver diseases and cancer. Here, we present the results of structure–activity relationship (SAR) studies, based around SR9238 (6) and SR9243 (7). This study led to identification of 16, 17, 19, and 38, which were more potent inverse agonists than SR9238 (6) and SR9243 (7) and inhibited expression of the fatty acid synthase gene in DU145 cells. We previously demonstrated that inhibition of FASN is correlated to the anticancer activity of SR9243 (7) and this suggests that new inverse agonists have great potential as anticancer agents. We identified compounds with distinct selectivity toward both LXR isoforms, which can be excellent tools to study the pharmacology of both isoforms. We employed molecular dynamic (MD) simulations to better understand the molecular mechanism underlying inverse agonist activity and to guide our future design.
DOI
10.1016/j.bioorg.2021.105540
Publication Date
2-1-2022
Recommended Citation
Elgendy, Bahaa; Griffett, Kristine; Hegazy, Lamees; Di Fruscia, Paolo; Sample, Kirby; Schoepke, Emmalie; Kamenecka, Theodore M.; and Burris, Thomas P., "Synthesis and structure activity relationship of the first class of LXR inverse agonists" (2022). Pharmaceutical and Administrative Sciences Faculty Publications. 85.
https://doi.org/10.1016/j.bioorg.2021.105540
https://collections.uhsp.edu/pharm-admin-sciences_pubs/85